Carfilzomib + Ibrutinib

Phase 2Small molecule

CChristian Buske

Carfilzomib + Ibrutinib is one of 50 small molecule programs targeting Macroglobulinemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MacroglobulinemiaActive, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

67 competitors in Macroglobulinemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

1 2

Rituxan

Roche

Phase 2

23 3

Leukeran

Akero Therapeutics

Phase 3

1 4

Darzalex

Johnson & Johnson

Phase 2

2 5

Calquence

AstraZeneca

Phase 2

2 6

Thalomid

Bristol-Myers Squibb

Phase 2

2 7

Velcade

SShilpa Grover, MD, MPH

Phase 2

11 8

Gazyva

Roche

Phase 2

1 9

Jaypirca

Eli Lilly

Phase 2

1 10

Ninlaro

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Macroglobulinemia

NCT04263480

Clinical

Trials by Indication[1]

Macroglobulinemia1 trial

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Active, not recruiting·CChristian Buske·Phase 2·NCT04263480·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carfilzomib + Ibrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carfilzomib + Ibrutinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carfilzomib + Ibrutinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Christian Buske company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChristian Buske

Carfilzomib + Ibrutinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Macroglobulinemia1 trial

References

Drug Info

Quick Facts

Related News